Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
Verified December 2014 by Dana-Farber Cancer Institute
Information provided by (Responsible Party):
Jennifer R. Brown, MD, PhD, Dana-Farber Cancer Institute
First received: August 15, 2005
Last updated: December 12, 2014
Last verified: December 2014
The purpose of this study is to investigate possible genetic factors that contribute to the development of lymphomas. The databank will be used to determine whether familial lymphomas have unique genetic characteristics different from sporadic lymphomas and to attempt to identify a gene that confers an increased risk of lymphoma.
Leukemia, Lymphocytic, Chronic
||Observational Model: Family-Based
Time Perspective: Prospective
||Establishing a Tumor Bank and Initial Analysis of Germline and Tumor-Related Genetic Alterations in Families With Multiple Lymphoproliferative Malignancies
Biospecimen Retention: Samples With DNA
Primary Outcome Measures:
- Genetic factors that contribute to the development of lymphomas and CLL [ Time Frame: Indefinite ] [ Designated as safety issue: No ]
Whole blood Cheek cells Paraffin blocks of tumor tissue
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||January 2020 (Final data collection date for primary outcome measure)
Next of Kin of deceased subject by lymphoma
Subject unaffected by lymphoma
Subject affected by lymphoma
- Patients who participate will be asked to complete detailed family and medical history questionnaires initially, with a follow-up questionnaire every year.
- Patients will be asked to supply a blood sample and possibly a mouthwash sample, both of which can be done by mail.
- Patients will be asked to consent to the release of their lymphoma tissue block for the purposes of the study.
- Patients will be given letters of invitation for their affected relatives to invite them to participate.
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Group 1: Next of kin of a relative who has died from lymphoma Group 2: Subjects who have a next of kin diagnosed with lymphoma and/or CLL Group 3: Subjects who have had or have non-Hodgkin's lymphoma, CLL or Hodgkin's disease and had a relative who also had lymphoma or CLL
- Any individual diagnosed with non-Hodgkin's lymphoma or Hodgkin's disease or chronic lymphocytic leukemia (CLL), who has a 1st degree relative (parent, sibling or child) with a lymphoproliferative disorder; or families in which the individual has a lymphoproliferative disorder, and an unusual clustering of frequent or premature solid tumors is also observed.
- Family members of the individual, either affected or unaffected with lymphoma, who are contacted by the individual and agree to participate in the study.
- Deceased family members may be included in the study. Public records such as death certificates may be used to confirm the history. Consent for medical records or tissue blocks will be obtained from the deceased family member's next of kin. The hierarchy of relatives defined as next of kin is spouse, offspring, parents and siblings. Archived tissue samples may be used for genetic research.
- Age > 18 years
- Subjects without a family history of lymphoma
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00131014
|Dana-Farber Cancer Institute
|Boston, Massachusetts, United States, 02115 |
|Contact: Jennifer R. Brown, MD, PhD 617-632-6692 email@example.com |
|Principal Investigator: Jennifer R. Brown, MD, PhD |
Dana-Farber Cancer Institute
||Jennifer R. Brown, MD, PhD
||Dana-Farber Cancer Institute
No publications provided
||Jennifer R. Brown, MD, PhD, Assistant Professor of Medicine, Dana-Farber Cancer Institute
History of Changes
|Other Study ID Numbers:
|Study First Received:
||August 15, 2005
||December 12, 2014
||United States: Institutional Review Board
Keywords provided by Dana-Farber Cancer Institute:
Chronic Lymphocytic Leukemia
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on May 26, 2015
Leukemia, Lymphocytic, Chronic, B-Cell
Immune System Diseases
Neoplasms by Histologic Type